Contact this trialFirst, we need to learn more about you.
Glutamate Receptor Antagonist
Basimglurant for Tuberous Sclerosis
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing basimglurant, a medicine that helps control seizures, in children, adolescents, and young adults with Tuberous Sclerosis Complex (TSC). Basimglurant works by blocking a specific receptor in the brain, which helps reduce seizures. The goal is to find the best dose that reduces seizures while being safe for patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service